Matteo Simonelli

Head of Early-Drug Development in Solid Tumors and Neuroncology

IRCCS Humanitas Research Hospital

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Matteo Simonelli is the Head of Early-Drug Development in Solid Tumors and Neuro-oncology at IRCCS Humanitas Research Hospital in Italy. His research focuses on innovative therapeutic strategies for brain tumors, particularly glioblastoma and other solid tumors, as evidenced by his recent publications on topics such as ADCs in brain metastases, proliferation-diffusion modeling, and the impact of immune checkpoint inhibitors. His work aims to advance understanding of treatment mechanisms and improve patient outcomes through clinical trials and translational research.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

ITALY

View details

GIOVANNI SAVINI

Humanitas University

ITALY

View details

Marta Scorsetti

Full Professor in Diagnostic Imaging and Radiotherapy

Humanitas University

ITALY

View details

Gianluigi Condorelli

Full Professor of Cardiology and Director of Post-Graduate School of Cardiology

Humanitas University

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Matteo Simonelli

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Proliferation-Diffusion Modeling in Glioblastoma: Impact of Supramaximal Resection on Survival

Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions

Preoperative Diffusion Tensor Imaging and Neurite Dispersion and Density Imaging in Isocitrate Dehydrogenase-Mutant Grade 2 and 3 Gliomas: Definition of Tumor-Related Epilepsy and Predictive Factors of Seizure Outcomes Based on a Single-Center Retrospective Case Series

Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events

Corrigendum to “PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives” [Cancer Treat. Rev. 131 (2024) 102850] (Cancer Treatment Reviews (2024) 131, (S0305737224001798), (10.1016/j.ctrv.2024.102850))

T Cell Features in Glioblastoma May Guide Therapeutic Strategies to Overcome Microenvironment Immunosuppression

Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

Brain metastases and next-generation anticancer therapies: a survival guide for clinicians

Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study

Collaborators (8)

Federico Pessina

Letterio Salvatore Politi

Marinos Kallikourdis

Pasquale Persico

Elisabetta Lazzarini

GIOVANNI SAVINI

Marta Scorsetti

Gianluigi Condorelli

Make your next move.